How do Janoshik and Medutest compare on the same ecnoglutide batch?

What I have: Janoshik · Medutest · ecnoglutide.

Both of these get recommended confidently by different people, which suggests neither is obviously right.

My constraints are cost, measurement resolution and how much handling I am prepared to do — in roughly that order.

Under what conditions does the answer flip?

Mechanically, results from Janoshik are only comparable to other Janoshik results, not to results from any other laboratory, because the methods differ.

A result significantly outside the database range for that vendor and compound is either a real difference in quality or a different material than the database entries.

The cost of testing is by sample submitted, not by parameter measured, so a single Janoshik result gives you purity, content and identity for less than most suppliers charge for purity alone.

Janoshik publishes summary statistics on their website, including the number of samples tested and the range of reported values, giving you a baseline for comparison.

I would use Janoshik for the first lot from a new supplier and occasionally for spot-checking, not for every lot.

Keep Janoshik results to compare across suppliers and across time.

On the detail: the single strongest value proposition of Janoshik is that they publish all results in a database indexed by vendor and compound, which lets you compare your result to hundreds of other users.

The database can be searched by vendor, by compound, by date range and by result value, making it easy to benchmark a new supplier against historical data.

Put another way, content assay uses a certified reference standard and quantifies against that standard under the same method conditions as the purity analysis.

The database has been publicly available for long enough that systematic biases in their reporting would be apparent and would have been flagged by users.

The practical summary: submit your first lot to Janoshik and check the database for that vendor.

Concretely, turnaround from sample submission to report is usually two to three weeks, which makes Janoshik practical for supplier qualification but not for lot-by-lot QC.

The purity method uses a linear gradient at a specified slope, which is published and reproducible — not a vendor-chosen method that could be optimised for a high number.

The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.

The limitation is that even Janoshik cannot catch every failure — they are testing a snapshot, not guaranteeing every vial.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

The short answer is that Janoshik is expensive, but the database of community results is worth the cost even if you only test your first lot from a new supplier.

Comparison across time on the same vendor's material — three lots of vendor X spread over six months — shows whether quality is trending or stable.

The relevant pharmacopoeial reference points here are the general chapters on peptide purity and on bacterial endotoxins; both specify method validation requirements that research-grade certificates almost never claim to meet, and the absence of that claim is itself information.

The caveat is that Janoshik is expensive, and cost-cutting on the first lot from a supplier might mean testing one vial rather than three.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.